SLC25A22 and epilepsy: We identified mutation of SLC25A22 [also called glutamate carrier 1 (GC1)], through exome sequencing of 400 Korean PWEs, developed a zebrafish slc25a22a mutant model using CRISPR-Cas9 and found that valproic acid (VPA) suppresses seizures in this model, suggesting Slc25a22a as a potential target for development of epilepsy treatments.